Published in Oncogene on January 06, 2005
Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res (2010) 4.19
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol (2013) 1.71
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov (2014) 1.58
Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A (2011) 1.20
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A (2013) 1.20
MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol (2013) 1.06
Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia (2009) 1.01
Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res (2012) 0.99
Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes Cancer (2013) 0.98
Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS One (2011) 0.98
Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget (2015) 0.88
The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation. Cell Death Dis (2013) 0.86
Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathol (2015) 0.82
Human neural crest cells contribute to coat pigmentation in interspecies chimeras after in utero injection into mouse embryos. Proc Natl Acad Sci U S A (2016) 0.78
Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. Am J Pathol (2015) 0.77
Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma. Sci Rep (2016) 0.76
Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma. Mol Cell Biol (2016) 0.76
Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers (Basel) (2017) 0.75
Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2013) 0.75
Expression array analysis of the hepatocyte growth factor invasive program. Clin Exp Metastasis (2015) 0.75
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
A draft sequence for the genome of the domesticated silkworm (Bombyx mori). Science (2004) 6.62
The incidences and mortalities of major cancers in China, 2009. Chin J Cancer (2013) 5.17
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology (2007) 3.34
[Trend analysis and projection of cancer incidence in China between 1989 and 2008]. Zhonghua Zhong Liu Za Zhi (2012) 3.15
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res (2009) 3.11
[Trend analysis of cancer mortality in China between 1989 and 2008]. Zhonghua Zhong Liu Za Zhi (2012) 3.10
Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res (2013) 2.88
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
Complete resequencing of 40 genomes reveals domestication events and genes in silkworm (Bombyx). Science (2009) 2.68
Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med (2009) 2.25
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25
Microarray-based gene expression profiles in multiple tissues of the domesticated silkworm, Bombyx mori. Genome Biol (2007) 2.21
Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet (2008) 2.21
Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc Natl Acad Sci U S A (2007) 2.15
HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem (2003) 2.08
Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function. J Am Soc Nephrol (2008) 2.04
Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res (2006) 1.94
Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A (2003) 1.90
Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci U S A (2006) 1.85
High expression of the Met receptor in prostate cancer metastasis to bone. Urology (2002) 1.83
Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis (2011) 1.81
Highly efficient and specific genome editing in silkworm using custom TALENs. PLoS One (2012) 1.80
Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol (2004) 1.65
Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS One (2008) 1.64
The decline in U.S. cancer mortality in people born since 1925. Cancer Res (2009) 1.61
HGF/SF-Met signaling in tumor progression. Cell Res (2005) 1.61
Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun (2012) 1.58
L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer (2006) 1.57
Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res (2005) 1.55
Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. Leuk Lymphoma (2010) 1.55
Enhanced serodiagnostic utility of novel Mycobacterium tuberculosis polyproteins. J Infect (2012) 1.52
Predicting drug-drug interactions: an FDA perspective. AAPS J (2009) 1.52
Cancer incidence and mortality in china, 2006. Chin J Cancer Res (2011) 1.50
Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res (2012) 1.49
The odorant binding protein gene family from the genome of silkworm, Bombyx mori. BMC Genomics (2009) 1.48
Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res (2004) 1.47
Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene (2002) 1.47
MicroRNAs of Bombyx mori identified by Solexa sequencing. BMC Genomics (2010) 1.46
Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat Genet (2011) 1.42
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A (2009) 1.42
Dealing with the complex drug-drug interactions: towards mechanistic models. Biopharm Drug Dispos (2015) 1.40
Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A (2005) 1.40
Implementing biosecurity education: approaches, resources and programmes. Sci Eng Ethics (2011) 1.39
The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci (2013) 1.38
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A (2002) 1.38
Adsorption of 2-mercaptobenzothiazole from aqueous solution by organo-bentonite. J Environ Sci (China) (2013) 1.38
Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene (2004) 1.37
Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res (2009) 1.35
Retracted MicroRNA expression profiling during the life cycle of the silkworm (Bombyx mori). BMC Genomics (2009) 1.35
Volume of preclinical xenograft tumors is more accurately assessed by ultrasound imaging than manual caliper measurements. J Ultrasound Med (2010) 1.35
Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis (2009) 1.35
Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res (2002) 1.32
Characterization and expression patterns of let-7 microRNA in the silkworm (Bombyx mori). BMC Dev Biol (2007) 1.32
Pivotal advance: characterization of mouse liver phagocytic B cells in innate immunity. J Leukoc Biol (2011) 1.32
Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A (2004) 1.31
Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res (2005) 1.29
Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci U S A (2009) 1.28
Human papillomavirus infection and sporadic breast carcinoma risk: a meta-analysis. Breast Cancer Res Treat (2010) 1.28
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res (2010) 1.28
Mig-6, signal transduction, stress response and cancer. Cell Cycle (2007) 1.28
Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci Rep (2013) 1.28
A gamma-glutamyl transpeptidase-independent pathway of glutathione catabolism to glutamate via 5-oxoproline in Arabidopsis. Plant Physiol (2008) 1.27
Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis (2008) 1.26
Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration. Clin Pharmacokinet (2015) 1.26
[An analysis of lung cancer mortality in China, 2004 - 2005]. Zhonghua Yu Fang Yi Xue Za Zhi (2010) 1.24
Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res (2009) 1.24
Cocirculation and evolution of two lineages of influenza B viruses in europe and Israel in the 2001-2002 season. J Clin Microbiol (2003) 1.24
Identification and expression pattern of the chemosensory protein gene family in the silkworm, Bombyx mori. Insect Biochem Mol Biol (2006) 1.22
Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum Antibodies (2003) 1.20
Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Hum Mol Genet (2011) 1.20
CRISPR/Cas9-mediated targeted mutagenesis in Nicotiana tabacum. Plant Mol Biol (2014) 1.20
Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A (2011) 1.20
Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer. Clin Gastroenterol Hepatol (2005) 1.20
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A (2013) 1.20
Cloning and heterologous expression of the cyclooctatin biosynthetic gene cluster afford a diterpene cyclase and two p450 hydroxylases. Chem Biol (2009) 1.19
Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol (2010) 1.18
Inhibition of Pkhd1 impairs tubulomorphogenesis of cultured IMCD cells. Mol Biol Cell (2005) 1.17
Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proc Natl Acad Sci U S A (2005) 1.16